bpc-157 clinical trials results Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- 157 to the 503A Bulks List for use in compounding for Federal health advisers are meeting

In the adjuvant arthritis (tail-application of 0.2 ml of Freund's adjuvant) studies (14 days, 30 days, one year), NaBPC157 (10 g or 10 ng/kg i.p.) was given as a single application (at 1 hour either before or following the application of Freund's adjuvant) or in a once-daily regimen (0-14 th day, 14-30 th day and 14 th day-one year)

Reporting suspected adverse reactions : If you experience a suspected side effect from an unlicensed product, please report it via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk)

Info here SKU: BPC5-001 Category: Peptide Specifications Reviews Reviews coming soon

Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options

Research confirms this consistently